Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Meredith

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 10, 2025
Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally MatureKaren Fritchie, Baptiste Ameline, Vanghelita Andrei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 14, 2020
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profileKrinio Giannikou, Zachary Zhu, Jaegil Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent GlioblastomaFabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, et al.
Neuro-Oncology|May 20, 2021
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial resultsWenya Linda Bi, Lakshmi Nayak, David M Meredith, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
Nature Communications|May 15, 2025
Gabapentinoids confer survival benefit in human glioblastomaJoshua D Bernstock, Mulki Mehari, Jakob V E Gerstl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2023
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive RandomizationRifaquat Rahman, Lorenzo Trippa, Eudocia Q Lee, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 10, 2025
Malignant Chondroblastoma: An Epigenetically Distinct Subtype of Chondroblastoma With a Predilection for the Skeletally MatureKaren Fritchie, Baptiste Ameline, Vanghelita Andrei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 14, 2020
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profileKrinio Giannikou, Zachary Zhu, Jaegil Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent GlioblastomaFabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, et al.
Neuro-Oncology|May 20, 2021
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial resultsWenya Linda Bi, Lakshmi Nayak, David M Meredith, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
Nature Communications|May 15, 2025
Gabapentinoids confer survival benefit in human glioblastomaJoshua D Bernstock, Mulki Mehari, Jakob V E Gerstl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2023
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive RandomizationRifaquat Rahman, Lorenzo Trippa, Eudocia Q Lee, et al.
Pageof 7